Quince Therapeutics Rebrands as IRulya Therapeutics with New Leadership

Key Facts

1Quince Therapeutics announced its relaunch as IRulya Therapeutics, focusing on the clinical development of LAM-001 for pulmonary disease.

2The company's common stock will begin trading on Nasdaq under the new symbol IRLA effective October 12, 2026.

3Management changes include the appointment of Brigette Roberts as CEO and John Militello as CFO.

Quince Therapeutics announced its relaunch as IRulya Therapeutics, focusing on the clinical development of LAM-001 for pulmonary disease. According to a GlobeNewswire statement, the company's common stock will begin trading on Nasdaq under the new symbol IRLA effective October 12, 2026. Management changes include the appointment of Brigette Roberts as CEO and John Militello as CFO.

QNCX closed at $29.36 on October 8, 2026, with the stock reaching a day high of $29.8 and a low of $26.65. This rebranding and leadership refresh aims to reposition the company within the biotech sector as it advances its lead clinical candidate.